Reduced insular γ‐aminobutyric acid in fibromyalgia by Foerster, Bradley R. et al.
ARTHRITIS & RHEUMATISM
Vol. 64, No. 2, February 2012, pp 579–583
DOI 10.1002/art.33339
© 2012, American College of Rheumatology
BRIEF REPORT
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Objective. Recent scientific findings have reinvig-
orated interest in examining the role of -aminobutyric
acid (GABA), the major inhibitory central nervous
system neurotransmitter, in chronic pain conditions.
Decreased inhibitory neurotransmission is a proposed
mechanism in the pathophysiology of chronic pain
syndromes such as fibromyalgia (FM). The purpose of
this study was to test the hypothesis that decreased
levels of insular and anterior cingulate GABA would
be present in FM patients, and that the concentration
of this neurotransmitter would be correlated with
pressure–pain thresholds.
Methods. Sixteen FM patients and 17 age- and
sex-matched healthy controls underwent pressure–pain
testing and a 3T proton magnetic resonance spectros-
copy session in which the right anterior insula, right
posterior insula, anterior cingulate, and occipital cortex
were examined in subjects at rest.
Results. GABA levels in the right anterior insula
were significantly lower in FM patients compared with
healthy controls (mean  SD 1.17  0.24 arbitrary
institutional units versus 1.42  0.32 arbitrary institu-
tional units; P  0.016). There was a trend toward
increased GABA levels in the anterior cingulate of FM
patients compared with healthy controls (P  0.06). No
significant differences between groups were detected in
the posterior insula or occipital cortex (P > 0.05 for all
comparisons). Within the right posterior insula, higher
levels of GABA were positively correlated with pressure–
pain thresholds in the FM patients (Spearman’s rho 
0.63; P  0.02).
Conclusion. Diminished inhibitory neurotrans-
mission resulting from lower concentrations of GABA
within the right anterior insula may play a role in the
pathophysiology of FM and other central pain syndromes.
Fibromyalgia (FM) is the prototypical “central”
chronic pain syndrome and is known to cause significant
distress and disability in patients. FM is challenging to
treat clinically and affects 2–4% of the US population
(1). Several studies have suggested that a central nervous
system–based processing problem causes the widespread
pain sensitivity in these individuals (2). To date, neuro-
imaging studies have largely used functional magnetic
resonance imaging (fMRI), positron emission tomo-
graphy (PET), and voxel-based morphometry tech-
niques to look at differences in neuronal function and
structure in the brains of patients with FM (2). There is
increasing interest in the application of proton magnetic
resonance spectroscopy (1H-MRS) to identify in vivo
neurochemical markers that may contribute to these
changes (3).
We and other investigators have previously used
1H-MRS to identify elevations of Glx (a combined
measure of glutamate and glutamine) in FM patients
within brain areas shown to be important in pain pro-
cessing, including the right insula (4,5). Since glutamate
is the main excitatory neurotransmitter in the central
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nervous system, these findings suggest that there may be
an up-regulation in the excitatory activity that contrib-
utes to the generalized hyperalgesic state in central
chronic pain syndromes such as FM.
In the central nervous system, -aminobutyric
acid (GABA) is the major inhibitory neurotransmitter,
and its role in pain processing has been recognized for
some time (6). Of direct relevance to our study is the
finding that lowering GABA levels within the insula en-
hances pain in an animal model (7). Studies in humans
also show proof of concept that GABA plays a critical
role in pain transmission, whereby baclofen, a GABAB
agonist, has demonstrated effectiveness in preclinical
models of acute and chronic pain (8). However, the failure
of baclofen as well as benzodiazepines (which primarily
bind to the GABAA receptor) to be effective analgesics
in clinical trials has diminished interest regarding the
role of GABA in chronic pain. Moreover, until recently,
there was no way to directly test whether GABA plays
a role in chronic pain states by measurement of this
neurotransmitter using conventional 1H-MRS techniques,
due to signal overlap and low signal intensity.
Several recent scientific findings have reinvigo-
rated interest in examining the role of GABA in chronic
pain. The drug sodium oxybate (also referred to as
-hydroxybutyrate) has been recently shown to be highly
effective in treating the pain, fatigue, and sleep difficul-
ties in patients with FM (9). Moreover, recent advances
in MR spectroscopy editing techniques now allow for
direct quantification of GABA using a conventional 3T
magnet (10). Therefore, in the present study, we inves-
tigated whether GABA levels in brain regions involved
in pain processing (i.e., the pain matrix, which includes
the anterior and posterior insula and anterior cingulate)
are reduced in patients with FM compared to age- and
sex-matched pain-free controls. We hypothesized that
reduced GABA concentrations could result in excitation
and hyperactivity in the insula, contributing to the
hyperalgesia that is thought to be partially responsible
for the symptoms seen in FM.
PATIENTS AND METHODS
Participants. Sixteen female patients with FM (mean 
SD age 37.2 12.8 years) and 17 age- and sex-matched healthy
control subjects (mean  SD age 36.1  11.7 years; P  0.79)
were studied. All participants gave written informed consent,
and the study protocol was approved by the University of
Michigan Institutional Review Board.
All participants with FM met the following inclusion
criteria: 1) a diagnosis of FM for at least 1 year, according to
the American College of Rheumatology 1990 criteria for FM
(11); 2) continued presence of pain for more than 50% of each
day; 3) limited introduction of any new medications or treat-
ments for control of FM symptoms during the study; 4) age
between 18 years and 75 years; 5) female; and 6) right-handed.
Participants with FM were excluded if they had any of the
following exclusion criteria: 1) current use or history of use of
opioid or narcotic analgesics; 2) history of substance abuse; 3)
presence of concurrent autoimmune or inflammatory disease
that causes pain; 4) concurrent participation in other thera-
peutic trials; 5) pregnant or nursing; and/or 6) severe psychi-
atric illnesses, including current major depression.
All healthy control subjects were 1) between age 18
years and 75 years, 2) female, and 3) right-handed. Exclusion
criteria for healthy controls were as follows: 1) having met the
American College of Rheumatology 1990 criteria for FM; 2)
having any chronic medical illness, including psychiatric disor-
ders; and 3) current pregnancy.
Magnetic resonance spectroscopy. The brains of all
subjects were imaged on a Philips Achieva 3T system, using an
8-channel receive head coil. We performed T1-weighted
3-dimensional MPRAGE imaging with an isotropic voxel
resolution of (0.9 mm)3. MR spectra were acquired from 3.0
cm  2.0 cm  3.0 cm volumes of the right anterior insula,
right posterior insula, anterior cingulate, and the occipital
midline cortex (Figure 1). The right insula was chosen for
detailed study, as we have previously demonstrated elevations
in the levels of Glx in the right insular region (4). The occipital
cortex was selected as a control region.
Single-voxel point-resolved spectroscopy (PRESS)
spectra (time to recovery [TR]/time to echo [TE] 2,000/35
msec) were acquired using VAPOR water suppression with 32
averages and a scan time of 1 minute for each voxel. For the
quantification of GABA, spectroscopy experiments using the
Mescher-Garwood point-resolved spectroscopy (MEGA-
PRESS) technique were performed, using the following para-
meters: TE 68 msec (TE1 15 msec, TE2 53 msec), TR 1.8
seconds, 256 transients of 2,000 data points, spectral width 2
kHz, frequency-selective editing pulses (14 msec) applied at
1.9 parts per million (the ON mode) and 7.46 ppm (the OFF
mode). Refocusing was performed using the amplitude-
modulated pulse GTST1203 (length 7 msec, bandwidth 1.2
kHz). The results from the conventional PRESS technique
were analyzed using LCModel. The MEGA-PRESS results
were analyzed using in-house postprocessing software in Mat-
lab, with Gaussian curve fitting to the GABA and inverted
N-acetylaspartate (NAA) peaks.
We measured GABA relative to the NAA signal in the
edited spectra (12) to calculate a ratio based on the concen-
tration of NAA, as generated by the MEGA-PRESS tech-
nique. After calculating this GABA:NAA ratio, we then mul-
tiplied this ratio by the NAA concentration, determined from
LCModel analysis of a short-TE PRESS spectrum of the same
voxel, which provides a concentration of NAA (in arbitrary
institutional units [AIU]) relative to the values for water.
Correction for cerebral spinal fluid was performed for each
voxel, using statistical parameter mapping with the program
SPM (Wellcome Trust Centre for Neuroimaging). Metabolite
concentrations were used only for statistical analysis from the
LCModel if the Crame´r-Rao bounds were less than 20%.
Experimental pain. Pressure–pain tenderness was as-
sessed prior to the MRS session using a previously described
method (13). Briefly, discrete pressure stimuli were applied to
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the subject’s left thumbnail using a stimulation device, which
eliminates any direct examiner–subject interaction. Pain inten-
sity ratings were recorded on the Gracely Box Scale question-
naire using a random presentation paradigm (13). During the
testing, stimulus pressures were determined interactively: a
computer program continuously adjusted stimulus pressure
levels to produce the same response distribution in each
subject. In 6 cases, pressure–pain testing was performed more
than 3 months prior to imaging.
Statistical analysis. Pressure–pain thresholds and
GABA levels were analyzed using PASW Statistics version 18.
We performed 2-sample t-tests to determine differences in
GABA levels between groups (FM patients versus healthy
controls) for the 4 brain regions. We next calculated Spear-
man’s correlations between pressure–pain thresholds and
GABA levels from each of the interrogated brain regions. P
values less than or equal to 0.05 were considered significant.
RESULTS
Comparison of brain GABA levels between FM
patients and healthy controls. Due to an inadequate
signal-to-noise ratio, the spectra determined by MEGA-
PRESS were not assessed in the anterior cingulate of 2
FM patients and in the occipital cortex of 3 FM patients.
Moreover, GABA spectra were unavailable for the
occipital cortex of 2 control subjects. To gauge repro-
ducibility, we remeasured the anterior cingulate GABA
concentration 5 times in the brain of 1 subject, with a
resulting coefficient of variance of 15%.
As shown in Figure 2, FM patients demonstrated
lower levels of GABA within the right anterior insula
(mean  SD 1.17  0.24 AIU) compared to healthy
controls (1.42 0.32 AIU; P 0.016). Conversely, there
was an unanticipated trend toward higher GABA levels
in the anterior cingulate of FM patients (1.46  0.25
AIU) compared to healthy controls (1.27  0.27 AIU;
P  0.06) (Figure 2). There were no significant differ-
Figure 1. Voxel placement and resulting spectrum on magnetic resonance spectroscopy. A, Axial and sagittal T1-weighted brain images obtained
from fibromyalgia patients show single-voxel placements (boxed areas) for the right anterior insula (ant Ins), right posterior insula (post Ins), anterior
cingulate (ACC), and occipital cortex (Occ). B, A representative proton magnetic resonance spectroscopy spectrum from the posterior insula is
shown, as determined using the multi-echo single-voxel point-resolved spectroscopy technique edited for -aminobutyric acid (GABA). The peak
for the combined measure of glutamine and glutamate (Glx) is resolved at 3.8 parts per million, and the peak for GABA is resolved at 3.0 ppm, with
an inverted N-acetylaspartate (NAA) peak at 2.0 ppm.
Figure 2. Levels of -aminobutyric acid (GABA) within the right
anterior insula (A), anterior cingulate (B), right posterior insula (C),
and occipital cortex (D) of individual patients with fibromyalgia (FM)
compared with healthy controls (HC). FM patients have reduced
concentrations of GABA in the right anterior insula, with a trend
toward elevated concentrations of GABA in the anterior cingulate, as
compared to healthy controls. There are no between-group differences
in the right posterior insula or occipital cortex. Circles represent
individual subjects; horizontal bars indicate the mean. AIU arbitrary
institutional units.
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ences in the mean level of GABA between the FM
patients and the healthy controls in either the right
posterior insula or the occipital cortex.
Positive correlation of posterior insula GABA
levels with pressure–pain thresholds. Pressure–pain
thresholds were obtained from 13 of the 16 patients with
FM. There was a significant positive correlation between
slightly intense pressure–pain thresholds and the right
posterior insula GABA levels in the FM patients (Spear-
man’s rho 0.63; P 0.02) (Figure 3). Patients with FM
who have lower levels of GABA within the right poste-
rior insula have higher sensitivity (i.e., lower thresholds)
to experimentally induced pressure–pain. No significant
correlations were detected in the right posterior insula
of the healthy controls or in any other brain regions for
either the FM patients or healthy controls.
DISCUSSION
Our results suggest that GABA may play a criti-
cal role in the pathophysiology of FM. The right anterior
insular levels of GABA were lower in the FM group
compared to the healthy control group, and there was a
positive correlation between the right posterior insular
GABA levels and sensitivity to experimental pain in FM
patients. Moreover, there was a trend toward higher
GABA levels in the anterior cingulate of FM patients
compared to healthy controls. These results suggest that
relatively reduced levels of GABA in the insular regions
are associated with FM symptoms.
The anterior insula is recognized as an area of the
brain that is involved with the affective dimension of
pain and emotional regulation, whereas the posterior
insula is proposed to be involved more with sensory
perception and processing of pain (14,15). Since the
levels of GABA were lower in the anterior insula of the
FM patients, this could suggest that GABA may be
involved in the modulation of the affective dimension of
pain in this patient population. Furthermore, the corre-
lation of posterior insula GABA levels and experimental
pain in FM patients may indicate that this inhibitory
brain neurotransmitter may contribute to “setting the
gain” on pain sensitivity in FM. A reduced level of
GABA in the insula may reflect lack of inhibitor re-
sponse and may therefore lead to heightened neuronal
activity, which results in amplified nociceptive response.
We also demonstrated a trend toward increased
GABA levels in the anterior cingulate in FM patients
compared with healthy controls. The anterior cingulate
has been implicated as an important pain-processing
region of the brain in a number of fMRI studies. As both
glutamatergic activity and GABAergic activity have
been shown to contribute to brain metabolism and
neuronal activity in functional imaging, it is unknown
what portion of the increased activity seen on fMRI or
PET imaging techniques is due to excitatory or inhibi-
tory mechanisms (16). If this trend toward higher GABA
levels in FM patients is indeed true, this may indicate
modulation on the part of the anterior cingulate to
inhibit neuronal response to chronic pain.
These alterations in GABA levels may represent
differences in concentrations of GABA in the presynap-
tic terminals, synaptic vesicles, or in GABA uptake
mechanisms. Although our 1H-MRS method cannot
discern these possibilities, our findings are consistent
with the notion of reduced GABAergic neurotransmis-
sion in pain-processing regions in FM. If this concept
proves to be true, one would predict that patients with
reduced insular levels of GABA may be more responsive
to pharmacologic interventions that would enhance
GABAergic neurotransmission. This hypothesis is con-
sistent with the positive results of a recent phase III
clinical trial of sodium oxybate, which acts as a GABA
agonist, for the treatment of FM (9).
Given the cross-sectional design of this study, we
cannot determine whether the reduced concentrations
of GABA are causing the pain in FM or whether the
reductions are a consequence of the pathologic pro-
cesses of the disease. Moreover, the number of subjects
Figure 3. Levels of -aminobutyric acid (GABA) within the right
posterior insula are positively correlated with pressure–pain thresholds
in patients with fibromyalgia. Results are shown as a scatterplot of
GABA concentrations in relation to slightly intense pressure–pain
thresholds in individual patients (solid circles); the regression line is
also shown. Correlations were assessed using Spearman’s rho. AIU 
arbitrary institutional units.
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included in the study was relatively small; however, our
cohort is comparable to those used in studies of other
functional and advanced neuroimaging techniques in
FM. We acknowledge that the measurements of GABA
and other metabolites by 1H-MRS represent the brain
tissue volume, and this technique does not differentiate
between intracellular and extracellular components. Ed-
ited measurements of GABA in 1H-MRS do not excite a
pure GABA signal and are limited by coediting of the
macromolecular signal. Although it is possible that the
effects we observed were driven by changes in this
macromolecular component, this study was based on
prior observations of a strong association between cen-
tral pain processing and GABAergic function, and we
therefore interpret our observations as representing
actual GABA levels.
We also did not collect information on the men-
strual cycle or depression symptoms of any of the
subjects, both of which may serve as potential mediators
in any findings related to the role of GABA. In 6 of the
FM patients, pressure testing was performed more than
3 months prior to imaging, which somewhat limits the
observed correlation between the right posterior insula
GABA levels and the pressure–pain thresholds. One
final limitation is the relatively large size of the MRS
voxels. The prescribed voxel size is required to achieve
adequate signal-to-noise ratio for quantification of
GABA using the MEGA-PRESS technique at 3T field
strength.
In conclusion, we find that GABA alteration in
the right insula is a potential pathologic mediator in FM.
Prior findings indicating the presence of allodynia and
hyperalgesia in these patients may therefore be ex-
plained by the alteration in inhibitory neurotransmission
within the insula and possibly the anterior cingulate. The
application of the MEGA-PRESS technique allows for
the study of inhibitory GABAergic neurotransmission.
These studies need to be replicated in larger cohorts of
FM patients, as well as in patients with other chronic
pain syndromes.
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